Humacyte, Inc. - Common Stock HUMA 深 滬
等待開盤 08-09 09:30:00 美东时间
2.48
+0.010
+0.40%
華盛通- 最 高2.7553
- 今 開2.48
- 成交量 1000.06万股
- 最 低 2.44
- 昨 收 2.47
- 總市值 3.84亿
- 52周最高 7.48
- 市盈率 靜 --
- 換手率 6.45%
- 52周最低 1.15
- 委 比 -26.69%
- 總股本 1.55亿
- 歷史最高 17.45
- 量 比 2.38
- 振 幅 12.77%
- 歷史最低 1.15
- 每 手 1
- 風險率 1.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多An Overview of Humacyte's Earnings
Humacyte (NASDAQ:HUMA) is gearing up to announce its quarterly earnings on Mond...
今天 01:10
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Humacyte, Inc. will release its second-quarter 2025 financial results on August 11, 2025, and hold a webcast and conference call at 8:00 a.m. ET. The company, focused on developing bioengineered human tissues, recently received FDA approval for its acellular tissue-engineered vessel (ATEV) for vascular trauma. The ATEV is also in late-stage trials for other applications, including hemodialysis and peripheral artery disease. Investors can join the...
08-07 12:00
韩国市场开始狂飙：动辄单日翻倍，Upbit日交易量破百亿美元
转载来源：火讯财经 文章来源： Zen 作者：Zen，PANews 7月，沉寂的韩国虚拟资产市场正式复苏，迎来了一次“量价齐升”的爆发行情...
07-24 23:55
Humacyte shares are trading higher after the company announced the first Symvess sale to a U.S. military treatment facility.
Humacyte shares are trading higher after the company announced the first Symves...
07-23 22:43
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.
07-09 20:53
美股牛股 | BTCS飙升111%！区块链业务取得重大进展；Humacyte升19%
BTCS飙升111%！区块链业务取得重大进展；Humacyte升19%，公司宣布获得美国国防物流局的Symvess ECAT批准>>
07-09 18:19
Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling over 100 points on Tue...
07-08 22:53
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
Humacyte's Symvess has received ECAT listing approval, making it available to healthcare professionals at U.S. Department of Defense and Department of Veterans Affairs facilities. FDA-approved in December 2024 for extremity vascular trauma, Symvess is now more accessible for treating military service members, veterans, and other patients. The approval underscores its potential for broader clinical use.
07-08 12:00
空间服务进化论：美置服务的多元服务力图谱
当前，物业行业面临上游地产波动、政策重构、需求升级与成本上涨等多重不确定性挑战，美置服务却以确定性服务锚定发展航向，在住宅、产园、医养等空间领域开辟出独特路径...
07-01 10:28
FLOOR & DECOR ANNOUNCES CORPORATE PARTNERSHIP WITH HABITAT FOR HUMANITY INTERNATIONAL
-Partnership unites shared values and resources to empower communities nationwide- ATLANTA, June 25, 2025 /PRNewswire/ -- Floor & Decor (NYSE: FND), the leading high-growth retailer speciali...
06-25 20:35
